Wex Pharmaceuticals Inc. Enrolls the First Patient in The Phase 2b Clinical Trial Evaluating the Efficacy and Safety of Halneuron In the Treatment of Chemotherapy-Induced Neuropathic Pain
VANCOUVER, BC / ACCESSWIRE / January 3, 2023 / WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that the first
Source: finanznachrichten.de